DCM
CBIO

DAFNA Capital Management’s Crescent Biopharma CBIO Stock Holding History

DAFNA Capital Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-280
Closed -$204K – 87
2016
Q2 		$204K Buy
+280
New +$193K 0.16% 77

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

DAFNA Capital Management's CBIO Position: Q3 2016 in Review

DAFNA Capital Management sold out of Crescent Biopharma (CBIO) in Q3 2016, closing a stake of 280 shares — an estimated $204K sold.

DAFNA Capital Management first reported a position in CBIO in Q2 2016 and held it in 1 quarter. The position peaked at $204K in Q2 2016. 48 funds tracked by Wall St. Rank hold CBIO as of Q3 2016.

  • DAFNA Capital Management reported no remaining Crescent Biopharma position as of Q3 2016 after selling out during the quarter.
  • DAFNA Capital Management sold 280 Crescent Biopharma shares in Q3 2016, an estimated $204K.
  • DAFNA Capital Management first reported a position in Crescent Biopharma in Q2 2016 and held it in 1 quarter.
  • DAFNA Capital Management's Crescent Biopharma position peaked at $204K in Q2 2016.
  • 48 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2016.

Based on DAFNA Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.